The Asia-Pacific Pruritus Therapeutics Market was valued at $2.0 billion in 2022 and is projected to reach $3.2 billion by 2032, registering a CAGR of 4.7% from 2023 to 2032.
Drugs used to treat pruritus are known as pruritus therapeutics. Pruritus causes itching due to a variety of conditions, including dry skin, allergies, and other illnesses of the skin. It is a skin condition that if left untreated, can lead to chronic pain and negatively impact the quality of life. For instance, pruritus can result in anxiety, attention-deficit or hyperactivity disorder, and sleep disturbance. If left untreated, it may also lead to systemic and mental disorders. When pruritus lasts for a longer period, it usually indicates a more serious underlying cause.
Eczema, also known as atopic dermatitis, can be brought on by an aggravated inflammatory reaction to a wide range of potential irritants, such as dust, environmental contaminants, animals, and specific foods. Furthermore, rashes, scaly patches, and itchy skin are the symptoms of atopic dermatitis on the face, arms, or legs. When people come into contact with chemicals that can hurt their skin, they can develop allergic contact dermatitis. Soaps, environmental contaminants, and jewelry made with potentially irritating materials are typical products that cause contact dermatitis.
Market Dynamics
The Asia-Pacific pruritus therapeutics market growth is driven by increase in prevalence of skin diseases, surge in product approvals in Japan and China, and rise in ageing population. There are many various skin disorders that produce pruritus, or itching, in the diverse population of the Asia-Pacific region. Atopic dermatitis, psoriasis, urticaria (hives), and other disorders are among them.
For instance, atopic dermatitis is a prevalent skin disease characterized by itchy, irritated skin. It is a chronic illness that often first manifests in childhood but can also affect adults. For the effective management of these conditions there is a growing demand for pruritus therapeutics which drives market growth.
Furthermore, older people are also more likely to have chronic illnesses, such as kidney or liver disease, which can cause pruritus as a side effect. In addition, pruritus can also be a side effect of several medications, and elderly people frequently utilize multiple medications. Therefore, as the number of elderly people rises, there is a demand for pruritus therapeutics, which boost the market growth.
Furthermore, increase in product approvals in Japan and China further contribute toward the market growth. For instance, in July 2023, Toray Industries, Inc. received approval from China’s National Medical Products Administration (NMPA) for REMITCH. REMITCH is used for the treatment of pruritus.
In addition, China is the second-largest healthcare market in the world and it continues to grow rapidly. The government's increased investment in healthcare, as well as a growing middle class can help afford better healthcare services, contribute to the rise in healthcare expenditure. This increased spending extends to pharmaceuticals, which further propels the market growth.
Furthermore, India has seen a significant rise in healthcare spending in recent years. Part of this increased spending is driven by the growing prevalence of chronic diseases, including skin conditions. Moreover, the Indian government has been introducing initiatives such as Ayushman Bharat, a national health protection scheme, aimed at providing access to necessary medical treatments for its vast population, which indirectly boosts healthcare spending and supports market growth.
However, lack of awareness about pruritus in low to middle income countries or rural areas negatively impacts the market growth. In rural areas, there is limited knowledge about skin conditions, their causes, symptoms, and available treatments. For instance, conditions such as atopic dermatitis may go undiagnosed or untreated due to a lack of understanding that persistent itching is a medical condition that can be treated. This lack of awareness can significantly reduce the demand for pruritus therapeutics.
In addition, lack of trained healthcare professionals specializing in dermatology in some areas limit the diagnosis of skin conditions and the prescription of pruritus therapeutics. On the other hand, emergence of biologic drugs for the treatment of pruritus is expected to create lucrative opportunity for the market growth. For instance, the biologic medicine Dupixent (dupilumab) targets the interleukin-4 and interleukin-13 proteins specific selectivity as they are known to be linked to atopic dermatitis. As a result, dupixent is highly effective in reducing atopic dermatitis-related pruritus.
The outbreak of COVID-19 has disrupted workflows in the healthcare sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. The Asia-Pacific Pruritus Therapeutics Market was moderately impacted during the pandemic due to disruption in supply of pharmaceutical drugs and delay in R&D activities. On the other hand, the adoption of telemedicine and sale of pruritus therapeutics through e-commerce websites boost the market growth during the forecast period.
Segmental Overview
The Asia-Pacific Pruritus Therapeutics Market is segmented on the basis of drug type, disease type, distribution channel, and country. On the basis of drug type, the market is classified into corticosteroids, antihistamines, local anesthetics, immunosuppressant, and others. As per disease type, the market is categorized into atopic dermatitis, allergic contact dermatitis, urticarial, and others. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies, and online providers. Country wise, the market is studied across Japan, China, South Korea, Taiwan and rest of Asia-Pacific.
By Drug Type:
The Asia-Pacific Pruritus Therapeutics Market is segmented into corticosteroids, antihistamines, local anesthetics, immunosuppressant, and others. The corticosteroid segment dominated the market in 2022 and is expected to remain dominant throughout the forecast period as it provides symptomatic relief to various conditions such as atopic dermatitis, urticaria, and others. In addition, corticosteroids are available in various forms such as creams, ointments, lotions, and tablets. Moreover, corticosteroids are cost-effective and is the key factor driving the growth of this segment.
By Drug Type
Corticosteroids segment held a dominant position in 2022 and is anticipated to grow at a fastest rate during the forecast period.
By Disease Type:
The Asia-Pacific Pruritus Therapeutics Market is segregated into atopic dermatitis, allergic contact dermatitis, urticarial, and others. The atopic dermatitis segment dominated the market in 2022 and is anticipated to continue this trend during the forecast period. This is attributed to surge in prevalence of atopic dermatitis. In addition, increase in awareness about various health conditions including atopic dermatitis and increase in research and development in the field of atopic dermatitis boost the growth of this segment.
However, others are expected to be the fastest growing segment during the forecast period, owing to increase in prevalence of prurigo nodularis and surge in occurrence of pruritus in patients suffering from chronic kidney disease.
By Disease Type
Atopic Dermatitis segment held a dominant position in the market in 2022 and the others segment is anticipated to grow at a fastest rate during the forecast period.
By Distribution Channel:
The Asia-Pacific Pruritus Therapeutics Market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores & retail pharmacies segment dominated the market in 2022 and is anticipated to remain dominant during the forecast period. This is attributed to easy accessibility and availability of pruritus therapeutics from drug stores.
On the other hand, online providers are expected to be the fastest growing segment during the forecast period, owing to the increase in number of e-pharmacy and shift of people’s preference toward online pharmacies.
By Country:
For Asia-Pacific region, the market is analyzed across Japan, China, South Korea, Taiwan, and Rest of Asia-Pacific. China accounted for a major share of the Asia-Pacific Pruritus Therapeutics Market in 2022 and is expected to maintain its dominance during the forecast period. The presence of large population with significant number of populations suffering from skin conditions such as urticarial, atopic dermatitis, and others, which are the major causes of pruritus and is the key factor boost the growth of pruritus therapeutics in China.
For instance, according to the World Allergy Organization Journal 2022, the prevalence of atopic dermatitis in the Singapore/Malaysia Chinese young adult population was 13.5%. Furthermore, expansion of healthcare facilities and advancement in therapeutic treatments further propels the market growth.
Japan is expected to grow at the highest CAGR rate during the forecast period. The market growth in this country is attributable to the highest proportions of elderly people that are more susceptible to skin conditions such as atopic dermatitis or urticaria. Furthermore, Japan has a highly developed healthcare system, with a strong focus on research and development in medicine. This facilitates the adoption of innovative treatments for pruritus, which further propels the market growth in this country.
In addition, the increase in product launches by the major key players in this country also contributed towards market growth. For instance, in August 2022, Maruho Co., Ltd., a leading pharmaceutical company, launched Mitchga Subcutaneous Injection 60mg Syringes in Japan, for the treatment of itching associated with atopic dermatitis. In addition, Dupixent Subcutaneous Injection 300mg Pen was launched in Japan for the treatment of atopic dermatitis in November 2020. Japan has a robust pharmaceutical sector, which helps to drive the growth of the pruritus therapeutics market.
Key players such as Viatris Inc., Sanofi S.A., and Eli Lilly and Company, are present in Japan, which further boost the market growth in this country. Japan offers profitable opportunities for key players operating in the Asia-Pacific Pruritus Therapeutics Market, thereby registering the fastest growth rate during the forecast period, owing to the rise in disposable income as well as increase in healthcare expenditure. Moreover, development of pharmaceutical industry and increase in R&D activities boost the market growth in this country.
Competition Analysis
Competitive analysis and profiles of the major players in the Asia-Pacific pruritus therapeutics include AbbVie Inc., Aspen Holdings, Cipla Ltd, Eli Lilly and Company, Haleon plc, Maruho co., Ltd, Sanofi S.A., Toray Industries Inc., Trevi Therapeutics, and Viatris Inc.
Recent Product Launches in the Asia-Pacific Pruritus Therapeutics Market
In September 2021, AbbVie Inc., a global pharmaceutical company, announced the launch of RINVOQ for the treatment of atopic dermatitis in Australia.
Recent Product Approval in the Asia-Pacific Pruritus Therapeutics Market
In July 2023, Sanofi Healthcare India Pvt. received marketing authorization for Dupixent for the treatment of moderate-to-severe atopic dermatitis in adults.
In July 2023, Toray Industries, Inc., and Meiji Seika Pharma Co., Ltd., received the U.S. Food and Drug Administration (FDA) approval to import and market REMITCH OD Tablets 2.5µg in Thailand for pruritus relief.
In December 2020, Eli Lilly and Company, a global leader in pharmaceutical industry, received approval for Ormiento Tablets 4mg, and Ormiento Tablets 2mg for the treatment of atopic dermatitis.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the Asia-Pacific pruritus therapeutics market analysis from 2022 to 2032 to identify the prevailing Asia-Pacific pruritus therapeutics market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the Asia-Pacific pruritus therapeutics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the Asia-Pacific pruritus therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Asia-Pacific Pruritus Therapeutics Market Report Highlights
| Aspects | Details |
 By Drug type |
|
 By Disease Type |
|
 By Distribution Channel |
|
 By Country |
|
 Key Market Players | Trevi Therapeutics, Cipla Ltd, Toray Industries Inc., Haleon plc, Aspen Holdings, AbbVie Inc., Sanofi S.A., Eli Lilly and Company, Viatris Inc, Maruho co., Ltd |
Analyst Review
The field of pruritus therapeutics is still nascent and is expected to gain significant attention over the years. There have been significant advances in pruritus therapies, which have simplified and made the treatment process more convenient for patients.
The market is expected to grow in the coming years, owing to an increase in prevalence of atopic dermatitis, surge in R&D activities, and introduction of new treatments in the market. Despite considerable advancements in dermatological research, the underlying mechanism of pruritus is still not fully understood. This lack of understanding makes it challenging to develop targeted and effective therapies which restraints market growth.
Furthermore, Asia-Pacific is expected to witness the significant growth during the forecast period, owing to availability of domestic market key players, surge in research and development, launch of new pruritus therapeutics, and surge in healthcare expenditure.
The total market value ofAsia-Pacific Pruritus Therapeutics Marketis $2.0 billion in 2022.
The forecast period forAsia-Pacific Pruritus Therapeutics Market is 2023-2032.
The market value of Asia-Pacific Pruritus Therapeutics Market in 2032 is $3.2 billion.
The base year is 2022 inAsia-Pacific Pruritus Therapeutics Market
Major key players that operate in the Asia-Pacific pruritus therapeutics market are AbbVie Inc., Aspen Holdings, Cipla Ltd, Eli Lilly and Company, Haleon plc, Maruho co., Ltd, Sanofi S.A., Toray Industries Inc., Trevi Therapeutics, and Viatris Inc.
The corticosteroids egment is the most influencing segment in the Asia-Pacific pruritus therapeutics market, as they are commonly prescribed as a first line treatment for pruritus due to their anti-inflammatory properties.
The Asia-Pacific pruritus therapeutics market growth is driven by an increase in the prevalence of skin disorders, surge in research and development activities for building a strong product pipeline and availability of over-the-counter (OTC) medications.
Pruritus, commonly known as itching, is a sensation that triggers the urge to scratch the skin. The causes of pruritus are various skin conditions such as eczema, psoriasis, hives, dermatitis, or fungal infections.
Loading Table Of Content...
